GH Research PLC Ordinary Shares
GHRSGH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative psychedelics and neuromodulators for mental health and neurological disorders. Headquarters in Ireland, the company specializes in the research and development of novel compounds aimed at addressing unmet medical needs related to psychiatric conditions.
Company News
Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical ...
U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus r...
GH Research announced presentation of long-term clinical data on GH001, a potential treatment for treatment-resistant depression, at the 38th Annual European College of Neuropsychopharmacology Congress in Amsterdam.
GH Research submitted a complete response to FDA's clinical hold on GH001, with one remaining issue regarding respiratory tract histology in rats. The Phase 2b trial showed a 73% remission rate at 6 months for treatment-resistant depression, with no serious adverse events and promising treatment outcomes.
GH Research PLC, a clinical-stage biopharmaceutical company, announced the submission of its complete response to the FDA regarding the clinical hold on its Investigational New Drug Application for GH001, its lead product candidate for treating treatment-resistant depression.
